Introduction
Biologics: Growth Factors MCQs With Answer is a targeted quiz resource for M.Pharm students studying Biological Evaluation of Drug Therapy. This set focuses on growth factors — endogenous proteins and peptides that regulate cell proliferation, differentiation, survival and tissue repair — and their therapeutic applications, mechanisms, production and safety considerations. The questions emphasize molecular signaling (RTKs, JAK/STAT, serine/threonine kinases), recombinant production and formulation issues (glycosylation, pegylation, expression systems), clinical uses (EPO, G-CSF, PDGF, VEGF inhibitors) and adverse effects. Use these MCQs to deepen conceptual understanding and prepare for advanced examinations and practical evaluations in biologic therapeutics.
Q1. What best defines a growth factor?
- Small molecule hormone that increases metabolic rate
- Protein or peptide that regulates cell proliferation, differentiation and survival
- Lipid mediator that induces vasodilation and inflammation
- Antibody that neutralizes cytokines
Correct Answer: Protein or peptide that regulates cell proliferation, differentiation and survival
Q2. Which receptor class is most commonly activated by epidermal growth factor (EGF)?
- G-protein coupled receptor (GPCR)
- Receptor tyrosine kinase (RTK)
- Ligand-gated ion channel
- Serine/threonine kinase receptor
Correct Answer: Receptor tyrosine kinase (RTK)
Q3. Vascular endothelial growth factor (VEGF) primarily promotes which biological process?
- Apoptosis of endothelial cells
- Angiogenesis and increased vascular permeability
- Inhibition of fibroblast proliferation
- Direct stimulation of erythropoiesis
Correct Answer: Angiogenesis and increased vascular permeability
Q4. Which intracellular signaling pathway is most directly associated with erythropoietin (EPO) receptor activation?
- cAMP-PKA pathway
- JAK/STAT pathway
- Notch signaling
- Wnt/β-catenin pathway
Correct Answer: JAK/STAT pathway
Q5. Recombinant human erythropoietin (rHuEPO) is primarily indicated for which condition?
- Neutropenia due to chemotherapy
- Chronic kidney disease-associated anemia
- Acute bacterial infections
- Hyperthyroidism
Correct Answer: Chronic kidney disease-associated anemia
Q6. Filgrastim is a recombinant form of which growth factor used clinically?
- Granulocyte colony-stimulating factor (G-CSF)
- Platelet-derived growth factor (PDGF)
- Vascular endothelial growth factor (VEGF)
- Transforming growth factor-beta (TGF-β)
Correct Answer: Granulocyte colony-stimulating factor (G-CSF)
Q7. The most common adverse effect associated with G-CSF therapy is:
- Hypertension and thrombosis
- Bone pain and musculoskeletal discomfort
- Severe hypoglycemia
- Renal failure
Correct Answer: Bone pain and musculoskeletal discomfort
Q8. Transforming growth factor-beta (TGF-β) is best characterized by which action?
- Stimulates erythroid progenitors exclusively
- Promotes extracellular matrix production and fibrosis
- Directly degrades collagen in wounds
- Acts as a potent angiogenic inhibitor only
Correct Answer: Promotes extracellular matrix production and fibrosis
Q9. Which therapeutic agent is a recombinant PDGF used topically to promote wound healing (e.g., diabetic foot ulcers)?
- Becaplermin (recombinant PDGF-BB)
- Ranibizumab (anti-VEGF Fab)
- Filgrastim (G-CSF)
- Interferon-alpha
Correct Answer: Becaplermin (recombinant PDGF-BB)
Q10. Platelet-derived growth factor (PDGF) primarily affects which cell types during repair?
- Neurons and oligodendrocytes
- Smooth muscle cells and fibroblasts
- Red blood cells
- Hepatocytes exclusively
Correct Answer: Smooth muscle cells and fibroblasts
Q11. Pegylation of a recombinant growth factor is performed mainly to:
- Decrease molecular size for better tissue penetration
- Increase half-life and reduce renal clearance
- Increase immunogenicity to boost immune response
- Modify the amino acid sequence to change receptor specificity
Correct Answer: Increase half-life and reduce renal clearance
Q12. A biosimilar is best described as:
- An identical chemical copy of a biologic like a small-molecule generic
- A biological product highly similar to a reference product with no clinically meaningful differences in safety, purity, and potency
- A synthetic molecule that mimics growth factor function exactly
- A labeling change to an existing biologic without manufacturing changes
Correct Answer: A biological product highly similar to a reference product with no clinically meaningful differences in safety, purity, and potency
Q13. Which production host is preferred when therapeutic growth factors require complex human-like glycosylation?
- Escherichia coli (E. coli)
- Chinese hamster ovary (CHO) cells
- Yeast (Saccharomyces cerevisiae) without modification
- Baculovirus-infected insect cells with no further processing
Correct Answer: Chinese hamster ovary (CHO) cells
Q14. Which growth factor family signals primarily through serine/threonine kinase receptors?
- EGF family
- TGF-beta family
- VEGF family
- Colony-stimulating factor family
Correct Answer: TGF-beta family
Q15. Which of the following is NOT classified as a colony-stimulating factor?
- Granulocyte colony-stimulating factor (G-CSF)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Erythropoietin (EPO)
- M-CSF (macrophage colony-stimulating factor)
Correct Answer: Erythropoietin (EPO)
Q16. Bevacizumab exerts its therapeutic effect by which mechanism?
- Blocking VEGF receptor tyrosine kinase activity intracellularly
- Binding VEGF-A ligand and preventing receptor interaction
- Acting as a soluble VEGF receptor agonist
- Stimulating endothelial progenitor cell proliferation
Correct Answer: Binding VEGF-A ligand and preventing receptor interaction
Q17. Use of erythropoiesis-stimulating agents (ESAs) in certain cancer patients has been associated with:
- Decreased tumor progression and improved survival in all cancer types
- Increased thromboembolic events and possible decreased survival in some malignancies
- Complete remission of solid tumors
- Universal protection against chemotherapy toxicity
Correct Answer: Increased thromboembolic events and possible decreased survival in some malignancies
Q18. Which assay is most appropriate to measure the biological activity of a recombinant colony-stimulating factor?
- Mass spectrometry quantifying peptide fragments
- Cell-based proliferation bioassay using responsive progenitor cells
- pH titration curve
- UV-visible spectroscopy absorbance at 280 nm
Correct Answer: Cell-based proliferation bioassay using responsive progenitor cells
Q19. Insulin-like growth factor (IGF) primarily mediates its effects through which mechanism?
- Activation of a receptor tyrosine kinase similar to the insulin receptor
- Binding to nuclear receptors and altering gene transcription directly
- Forming ion channels in the plasma membrane
- Acting as a transcription factor in the cytosol
Correct Answer: Activation of a receptor tyrosine kinase similar to the insulin receptor
Q20. A major challenge in developing therapeutic growth factors as biologics is:
- Their inability to bind any cellular receptors
- Manufacturing complexity including correct folding, glycosylation and consistent bioactivity
- Their solubility in organic solvents only
- The complete lack of any immunogenicity in humans
Correct Answer: Manufacturing complexity including correct folding, glycosylation and consistent bioactivity
